Therefore, the slight increase in the incidence of hematological toxicities might also be due to no use of prophylactic G-CSF. Crucially, these additional events were manageable using opportune symptomatic treatment such as anti-infection and G-CSF and did not translate into an increased risk of fatal AEs and death. This evidence concerns the gene CSF3 and infection.